You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Rapid Response Vaccines for Botulinum Neurotoxins

    SBC: Iterative Therapeutics Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNTs) are the most potent protein toxins known. Given their potent toxicity and their potential use in bio-warfare scenarios, BoNTs are included among the Category A select agents. The currentlyavailable pentavalent toxoid vaccine requires multiple boosters before being effective, and protects unequally against the different BoNT serotyp ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. A Rapid Point-of-care Diagnostic for Neisseria gonorrhoeae STDs

    SBC: NetBio, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Improved diagnosis of Neisseria gonorrhoeae (GC) infections represents a critical unmet medical need. The CDC estimates that approximately 700,000 people are infected by GC annually, with approximately half of these cases reported. The clinical spectrum of GC infection includes urethritis and cervicitis, pelvic inflammatory disease (PID), and disseminated disea ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Rapid screening tool for antibiotic resistant pathogens

    SBC: Resonant Sensors Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): The innovation presented in this proposal is a new class of label-free biochemical sensors with applicability in point of care (POC) medical diagnostics. The goal of the project to develop commercial biochip systems with compelling performance metrics targeted for rapid screening of an array of antibiotic resistant microbials in a clinical setting. The biochips ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Tissue Scaffold of High Strength and Porosity

    SBC: BIO2 TECHNOLOGIES, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): According to the Center of Disease Control and Prevention, arthritis is the greatest single cause of chronic pain and disability among Americans .2,3 Currently there is no cure for osteoarthritis, only medication and surgical procedures are available to alleviate the pain and discomfort associated with this degenerative bone disease. Current surgical treatment ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Amelioration of Claustrophobia and Disruptive Patient Motion in MR Imaging

    SBC: HYPNALGESICS, LLC            Topic: NCCAM

    DESCRIPTION (provided by applicant): Claustrophobia and disruptive patient motion are common impediments to MRI examination, but they may be prevented or ameliorated with a non-pharmacologic behavioral intervention administered by trained staff. The potential benefits of such an intervention are highly significant, considering that the alternatives are to cancel the study or administer sedation. I ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Virus-Targeted Therapy for Malignancies

    SBC: Phoenicia Biosciences, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Epstein-Barr virus (EBV) is associated with a number of human malignancies for which there are presently few effective treatments. Lymphoid malignancies caused by, or associated with, Epstein-Barr virus include Burkitt's lymphoma, T/NK lymphomas, some T- and B-cell lymphomas, approximately half of Hodgkin's lymphomas and all post-transplant lymphopro ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Rapid Testing of Drug-Resistant BCR-ABL(+)Leukemia Cells

    SBC: BIOSENSE TECHNOLOGIES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Resistance to chemotherapeutic drugs is an ongoing problem that results in eventual treatment failures or suboptimal patient outcomes. In cancer cells treated with drugs to which they are sensitive, the stress responseis the first step in the subsequent cascade leading to cell death (apoptotic, necrotic or autophagy). The recent availability of a sensing modali ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. HEPylated G-CSF: Drug with Safer, Enhanced Delivery for Neutropenia Treatment

    SBC: CAISSON BIOTECH, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Poly[ethylene glycol] (PEG) polymers are widely used by pharma to enhance the physical, chemical, and/or biological nature of promising drug candidates. The process of adding PEG polymers to drug cargo is termed PEGylation and has resulted in several Billion/year drugs. PEGylation protects the cargo when in the body and prolongs therapeutic action. For patient ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Screening of FoxA1-ER-DNA disruptors for development of breast cancer therapeutic

    SBC: Proteovista LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Estrogen receptor a (ERa) is the major therapeutic target for breast cancer, and ERa binding at target genes in breast cancer cells is guided by DNA binding pioneer factor proteins such as FoxA1. Although tamoxifen is asuccessful therapeutic for suppressing ER-mediated gene regulation, resistance to tamoxifen occurs in most breast cancer patients within five ye ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. A new paradigm for antibody-directed conjugates

    SBC: CENTROSE LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Non-small cell lung cancer (NSCLC) is among the most common and lethal cancers yet, the current standard of care for advanced stage NSCLC provides only modest improvements in overall survival or quality of life. Thus,there exists a significant unmet need for new effective therapies to treat NSCLC. Herein we describe an innovative new type of antibody drug conj ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government